Login
$FATE
$1.13 -$0.01 (0.82%) After hours

$FATE SEC Filings

Filed On Filing
12 Nov 2026 EFFECT
12 Nov 2026 424B5
09 Nov 2026 SCHEDULE 13D/A
05 Nov 2026 S-3
05 Nov 2026 424B5
05 Nov 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

Fate Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:

05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN

04 Nov 2026 Form 4: Adawi Kamal, Chief Financial Officer

Sold 6,582 shares ($13.5K)

03 Nov 2026 144
28 Sep 2026 8-K: Other Events

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

13 Aug 2026 S-8
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge

05 Aug 2026 Form 4: Tahl Cindy, See Remarks

Sold 38,800 shares ($95.4K)

05 Aug 2026 Form 4: Valamehr Bahram, Director

Sold 43,947 shares ($108K)

04 Aug 2026 144
04 Aug 2026 144
08 Jul 2026 SCHEDULE 13G/A
15 Jun 2026 Form 4: Redmile Group, Llc, Director and 1 other

Granted 87,900 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support